Linda E Carlson1, Kirk Warren Brown. 1. Department of Psychosocial Resources, Holy Cross Site, Alberta Cancer Board, 2202 2nd Street S.W., Calgary, Alberta, Canada T2S 3C1. lcarlso@ucalgary.ca
Abstract
OBJECTIVES: This study examined the construct and criterion validity of the Mindful Attention Awareness Scale (MAAS) in cancer outpatients, using matched community members as controls. METHODS: Cancer outpatients (n=122) applying for enrollment in a mindfulness-based stress reduction (MBSR) program completed the MAAS and measures of mood disturbance and stress. Local community members (n=122) matched to the patients on gender, age, and education level completed the same measures. RESULTS: The single-factor structure of the MAAS was invariant across the groups. Higher MAAS scores were associated with lower mood disturbance and stress symptoms in cancer patients, and the structure of these relations was invariant across groups. CONCLUSIONS: The MAAS appears to have appropriate application in research examining the role of mindfulness in the psychological well-being of cancer patients, with or without comparisons to nonclinical controls.
OBJECTIVES: This study examined the construct and criterion validity of the Mindful Attention Awareness Scale (MAAS) in cancer outpatients, using matched community members as controls. METHODS:Cancer outpatients (n=122) applying for enrollment in a mindfulness-based stress reduction (MBSR) program completed the MAAS and measures of mood disturbance and stress. Local community members (n=122) matched to the patients on gender, age, and education level completed the same measures. RESULTS: The single-factor structure of the MAAS was invariant across the groups. Higher MAAS scores were associated with lower mood disturbance and stress symptoms in cancerpatients, and the structure of these relations was invariant across groups. CONCLUSIONS: The MAAS appears to have appropriate application in research examining the role of mindfulness in the psychological well-being of cancerpatients, with or without comparisons to nonclinical controls.
Authors: Bruce Barrett; Mary S Hayney; Daniel Muller; David Rakel; Ann Ward; Chidi N Obasi; Roger Brown; Zhengjun Zhang; Aleksandra Zgierska; James Gern; Rebecca West; Tola Ewers; Shari Barlow; Michele Gassman; Christopher L Coe Journal: Ann Fam Med Date: 2012 Jul-Aug Impact factor: 5.166
Authors: Mary Catherine Beach; Debra Roter; P Todd Korthuis; Ronald M Epstein; Victoria Sharp; Neda Ratanawongsa; Jonathon Cohn; Susan Eggly; Andrea Sankar; Richard D Moore; Somnath Saha Journal: Ann Fam Med Date: 2013 Sep-Oct Impact factor: 5.166
Authors: S Jedel; A Hoffman; P Merriman; B Swanson; R Voigt; K B Rajan; M Shaikh; H Li; A Keshavarzian Journal: Digestion Date: 2014-02-14 Impact factor: 3.216
Authors: Linda Witek-Janusek; Kevin Albuquerque; Karen Rambo Chroniak; Christopher Chroniak; Ramon Durazo-Arvizu; Herbert L Mathews Journal: Brain Behav Immun Date: 2008-03-21 Impact factor: 7.217
Authors: Anna L Hawkes; Kenneth I Pakenham; Kerry S Courneya; Sara Gollschewski; Peter Baade; Louisa G Gordon; Brigid M Lynch; Joanne F Aitken; Suzanne K Chambers Journal: BMC Cancer Date: 2009-08-18 Impact factor: 4.430